Metagenomi Therapeutics Inc(MGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.49 | Insider Own | 21.07% | Shs Outstand | 37.8M | Perf Week | 1.72% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 24.61% | Insider Trans | 0.11% | Shs Float | 29.8M | Perf Month | -21.68% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | -0.64 | Inst Own | 16.3% | Short Float | 4.33% | Perf Quarter | -30.24% |
| Income | -0.09B | P/S | 2.31 | EPS this Y | -5.63% | Inst Trans | -1.46% | Short Ratio | 8.47 | Perf Half Y | -39.84% |
| Sales | 0.01B | P/B | 0.28 | EPS next 5Y | 7.64% | ROA | -41.91% | Short Interest | 1.29M | Perf YTD | -48.75% |
| Book/sh | 2.98 | P/C | 0.26 | EPS past 3/5Y | -26.57% -42.49% | ROE | -60.61% | 52W High | -68.43% ($2.63) | Perf Year | -64.67% |
| Cash/sh | 3.19 | P/FCF | - | Sales past 3/5Y | 13.59% 219.15% | ROIC | -64.88% | 52W Low | 10.69% ($0.75) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.97% | Gross Margin | 61.92% | Volatility(W/M) | 10.68% 7.82% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -3.8 | Sales Y/Y TTM | -59.84% | Oper. Margin | -741.58% | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.5 | EPS Q/Q | -36.21% | Profit Margin | -689.2% | RSI (14) | 35.82 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.5 | Sales Q/Q | -103.02% | SMA20 | -6.76% ($0.89) | Beta | 0.71 | Target Price | $7 |
| Payout | - | Debt/Eq | 0.34 | Earnings | 2026/8/10 | SMA50 | -21.09% ($1.05) | Rel Volume | 0.47 | Prev Close | $0.82 |
| Employees | 119 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | -31.98% -108.54% | SMA200 | -36.05% ($1.3) | Avg Volume(3M) | 0.15M | Price | $0.83 |
| IPO | 2024/2/9 | Option/Short | No/Yes | Trades | 161 | Volume | 72,041 | Change | 1.03% |
A pioneering biotech company advancing CRISPR, a next-generation gene-editing technology, to develop therapeutics for hemophilia and metabolic diseases.
Over the past 1 year, on the lower side
68% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
MGX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -5.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $231. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 16.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #449 of 594 in the industry
Based on market cap of $31M.
FLNA#445 Filana Therapeutics Inc $32M PER - 
ESLA#446 Estrella Immunopharma Inc $32M PER - 
AARD#447 Aardvark Therapeutics Inc $32M PER - 
ALGS#448 Aligos Therapeutics Inc $31M PER - MGX#449 Metagenomi Therapeutics Inc $31M PER - 
FAQ
What kind of company is MGX?
MGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MGX?
The market cap of MGX is approximately $31M, ranking 5,063 within its sector.
What is the 52-week high and low for MGX?
MGX has recorded a 52-week high of $2.63 and a low of $0.75.
